Blood Cancer Diagnostics Market Size & Growth Forecast 2026–2035, By Segments (Product, Test, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Blood Cancer Diagnostics Market size was worth USD 11.33 Billion in 2025 and is expected to grow at a 6.9% CAGR between 2026 and 2035, reaching USD 22.08 Billion by 2035. The industry revenue for 2026 is assessed at USD 12.01 billion.
Get more details on this report
Request Free Sample ReportBlood Cancer Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 39.96% share, supported by advanced diagnostic infrastructure, widespread molecular testing, and high clinical testing volumes across hospitals and cancer centers.
- Asia Pacific is growing at a 7.8% CAGR, driven by expanding laboratory capacity, improved access to cancer testing, and increasing adoption of advanced diagnostic methods.
Segment Momentum
- Assay Kits and Reagents accounted for 69.5% of the market in 2025 due to their essential role in routine testing, supporting standardized sample preparation, reliable detection, and consistent diagnostic workflows across laboratories.
- Molecular Test is the fastest-growing segment because it provides more specific disease characterization by detecting genetic and molecular changes, supporting increasingly precision-focused diagnostic decision-making.
Market Expansion Drivers
- Increasing incidence of leukemia and related malignancies driving demand for advanced diagnostic testing.
- Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision.
- Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the blood cancer diagnostics market include Danaher Corporation (United States), Abbott Laboratories (United States), Illumina, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), QIAGEN N.V. (Netherlands), Adaptive Biotechnologies Corporation (United States), Quest Diagnostics Incorporated (United States), SOPHiA GENETICS SA (Switzerland), InVivoScribe, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
A rising patient pool with leukemia, lymphoma, and related hematologic malignancies is pushing care providers to rely more heavily on tests that can classify disease subtype, detect progression earlier, and guide treatment selection with greater confidence. In the blood cancer diagnostics market, This transitions demand away from basic screening alone toward integrated diagnostic workflows that combine immunophenotyping, cytogenetics, molecular assays, and confirmatory pathology, since treatment decisions often depend on precise characterization at diagnosis and during follow-up. As clinicians manage more complex case volumes, laboratories and hospitals increase adoption of higher-value diagnostic platforms that can support faster turnaround and more granular disease profiling, reinforcing market demand for advanced blood cancer testing.
Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision
Ongoing improvements in next-generation sequencing and molecular diagnostics are changing how blood cancers are identified by enabling the detection of actionable mutations, chromosomal alterations, and minimal residual disease with greater sensitivity and shorter reporting timelines. For the blood cancer diagnostics market, these capabilities influence purchasing and test adoption because oncologists increasingly need diagnostic outputs that do more than confirm malignancy; they need data that can refine risk stratification and align patients with targeted therapies. This is driving demand for platforms and assay menus that consolidate multiple biomarkers into a single workflow, encouraging market growth as laboratories prioritize technologies that improve both clinical confidence and operational efficiency.
Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation
Capital flowing into personalized medicine and liquid biopsy development is accelerating the shift toward less invasive, biomarker-rich testing approaches that fit the longitudinal nature of blood cancer management. In the blood cancer diagnostics market, this investment supports the commercialization of assays designed for treatment selection, response monitoring, and relapse detection, creating stronger demand for diagnostic tools that can be used repeatedly without the limitations of more invasive sampling. The result is a pipeline of more specialized and clinically integrated testing solutions, with diagnostic developers, reference laboratories, and healthcare systems aligning around platforms that strengthen market development through precision-led care pathways.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing incidence of leukemia and related malignancies driving demand for advanced diagnostic testing | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in NGS and molecular diagnostics improving blood cancer detection speed and precision | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Expanding investment in personalized medicine and liquid biopsy technologies enhancing diagnostic innovation | 1.50% | Moderate | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 39.96% share of the blood cancer diagnostics market in 2025, bolstered by its established diagnostic infrastructure, broad availability of advanced testing platforms, and routine integration of specialized hematologic assays into clinical workflows. The region’s leadership is aided by high testing volumes across hospitals, cancer centers, and reference laboratories, where early detection, disease classification, and treatment monitoring depend on consistent use of molecular and pathology-based diagnostics. Strong clinician access to specialized care pathways also helps sustain demand for comprehensive diagnostic workups in everyday practice.
Asia Pacific is projected to expand at a 7.8% CAGR over the forecast period in the blood cancer diagnostics market, driven by rising access to cancer testing, ongoing expansion of laboratory capacity, and broader adoption of advanced diagnostic methods across major healthcare systems. Growth is being accelerated by improving detection pathways as more patients enter formal oncology care and providers increase use of precise diagnostic tools for leukemia, lymphoma, and myeloma evaluation. As healthcare delivery becomes more organized across urban and developing treatment networks, practical uptake of blood cancer testing is increasing across both public and private settings.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Advanced Laboratory IntegrationGermany emphasizes highly standardized laboratory diagnostics supported by molecular testing and pathology expertise. Diagnostic providers collaborate with healthcare institutions to improve testing quality and strengthen clinical decision-making for blood cancer management.
France 🇫🇷
Clinical Diagnostics AlignmentFrance supports blood cancer diagnostics through coordinated clinical pathways and increasing adoption of molecular testing techniques. Laboratories prioritize accurate disease characterization and standardized testing approaches that enhance treatment selection and patient management.
Italy 🇮🇹
Specialized Diagnostic NetworksItaly expands blood cancer diagnostics through specialized laboratory networks and wider availability of advanced testing methods. Healthcare providers focus on improving diagnostic consistency and supporting multidisciplinary care for hematologic malignancies.
Japan 🇯🇵
Molecular Testing ExpansionJapan continues integrating advanced molecular diagnostic technologies into blood cancer care pathways. Healthcare organizations in Japan focus on improving diagnostic accuracy through genomic analysis and efficient laboratory workflows that support individualized treatment strategies.
South Korea 🇰🇷
Precision Oncology SupportSouth Korea strengthens blood cancer diagnostics through expanded use of genomic technologies and digital laboratory capabilities. Diagnostic companies collaborate with hospitals to deliver comprehensive testing solutions that improve disease classification and therapeutic decision-making.
United States 🇺🇸
Precision Diagnostic AdoptionThe U.S. blood cancer diagnostics market prioritizes molecular testing, genomic profiling, and advanced laboratory technologies for earlier disease characterization. Healthcare providers continue adopting precision diagnostics that support personalized treatment planning and ongoing disease monitoring.
Segment Leadership and Growth Trends
Blood Cancer Diagnostics Market Share (%), Product, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportAssay Kits and Reagents held a 69.5% share of the blood cancer diagnostics market in 2025, reflecting their central role in routine and repeat testing across diagnostic workflows. Their leadership is maintained through the fact that blood cancer diagnostics depend on consistent, standardized consumables that support sample preparation, detection, and result reliability across laboratories and clinical settings. The same operational dependence is also driving continued growth, as rising testing volumes and the need for dependable, workflow-compatible diagnostic inputs make Assay Kits and Reagents the most actively adopted product category in the blood cancer diagnostics market.
Test Segment Analysis: Blood Tests (Largest Segment) vs Molecular Test (Fastest-Growing Segment)
By 2025, Blood Tests accounted for a 39.01% share of the blood cancer diagnostics market, making them the leading test segment due to their routine use as an initial diagnostic and monitoring tool. Their position is underpinned by broad clinical familiarity, practical integration into standard care pathways, and their role in providing accessible, repeatable information for evaluating hematologic abnormalities. These factors keep Blood Tests firmly established across the blood cancer diagnostics market, particularly where regular assessment is essential.
Molecular Test is emerging as the fastest-growing segment in the blood cancer diagnostics market because it addresses the increasing need for more specific disease characterization beyond conventional testing. Its momentum is being underpinned by the practical value of detecting genetic and molecular changes that can refine diagnosis and support more targeted clinical decision-making. Compared with alternative test types, Molecular Test is gaining traction as care settings place greater emphasis on precision-oriented evaluation in blood cancer diagnostics.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Assay Kits and Reagents | Assay Kits and Reagents | Assay Kits and Reagents |
| Test | Blood Tests, Imaging Tests, Biopsy, Molecular Test | Blood Tests | Molecular Test |
| End Use | Hospitals and Clinics, Diagnostic Labs, Research Institutes | Hospitals and Clinics | Hospitals and Clinics |
Competitive Landscape and Market Positioning
1. Danaher Corporation (United States)
2. Abbott Laboratories (United States)
3. Illumina Inc. (United States)
4. Bio-Rad Laboratories Inc. (United States)
5. QIAGEN N.V. (Netherlands)
6. Adaptive Biotechnologies Corporation (United States)
7. Quest Diagnostics Incorporated (United States)
8. SOPHiA GENETICS SA (Switzerland)
9. InVivoScribe Inc. (United States)
The blood cancer diagnostics market is witnessing rapid advancements in molecular testing, biomarker identification, and precision diagnostic platforms aimed at improving early detection accuracy. Investments in next-generation sequencing and AI-assisted diagnostic analysis are enhancing clinical decision-making capabilities. Rising demand for personalized oncology care is further driving innovation across the market landscape.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Predicta Biosciences | May-26 | Predicta Biosciences appointed Dr. Craig L. Tendler, a former senior oncology executive at Janssen, to its Board of Directors. This strategic appointment reinforces the company’s leadership in precision oncology diagnostics and is intended to accelerate the commercialization of its molecular diagnostic platform for hematologic malignancies. |
| Leukaemia Project Foundation | Oct-25 | The Leukaemia Project Foundation partnered with the JoyNews Impact Makers Foundation to launch a project for building Ghana’s first specialized Centre for Hematology and Clinical Genetics. This initiative aims to establish critical national infrastructure for blood cancer diagnostics, clinical genetics services, and specialized patient care. |
| Asuragen | Mar-24 | Asuragen received Class C Certification under the EU In Vitro Diagnostic Regulation (IVDR) for its QuantideX qPCR BCR-ABL IS Kit. The certification validates the kit’s performance in monitoring Chronic Myeloid Leukemia (CML) patients by quantifying BCR-ABL1 transcripts, ensuring compliance with updated European diagnostic standards. |
| Adaptive Biotechnologies | Dec-23 | Adaptive Biotechnologies released new clinical datasets for its clonoSEQ assay at the 65th ASH Annual Meeting. The data highlights the expanded utility of minimal residual disease (MRD) testing in clinical practice and trial environments, providing strong evidence for using standardized MRD monitoring in blood cancer patient care. |
| Abbott | Oct-23 | The FDA approved Abbott’s RealTime IDH1 Assay as a companion diagnostic for use with Servier Pharmaceuticals' Tibsovo (ivosidenib). This approval enables the precise identification of IDH1 gene mutations in patients with relapsed or refractory Myelodysplastic Syndromes (MDS), facilitating targeted therapy selection. |
| Cepheid | May-23 | Cepheid, a Danaher subsidiary, received CE mark approval for its Xpert NPM1 Mutation test, a molecular diagnostic tool for Acute Myeloid Leukemia (AML). By utilizing automated real-time RT-PCR technology to quantify mutant NPM1 mRNA transcripts, the test provides an accurate and standardized solution for AML monitoring in Europe. |
| QIAGEN | Mar-23 | QIAGEN entered a strategic partnership with Servier to develop a companion diagnostic test for the IDH1 inhibitor Tibsovo. The initiative focuses on utilizing the QIAGEN Rotor-Gene Q MDx platform to detect IDH1 mutations in AML patients, aiming to improve therapeutic stratification and treatment efficacy. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Blood Cancer Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Blood Cancer Diagnostics Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much revenue does the blood cancer diagnostics market generate?
How much is the blood cancer diagnostics industry expected to grow by 2035?
How is the rising incidence of blood cancers influencing diagnostic workflow adoption?
What role are molecular diagnostics and NGS playing in transforming testing demand in this market?
Why do Assay Kits and Reagents lead the blood cancer diagnostics market?
Which test segment is expanding the fastest in the blood cancer diagnostics market?
Why does North America dominate the blood cancer diagnostics market?
What is fueling growth in Asia Pacific blood cancer diagnostics?
What are the prominent companies operating in the blood cancer diagnostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization